Alivus Life Sciences Limited
ALIVUS.BO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$173.76B
Close$
$756.68
49.5% downside
Current Fair Value
49.5% downsideOvervalued by 49.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $173.76 Billion |
|---|---|
| Enterprise Value | $174.30 Billion |
| Annual dividend | $5.00 |
| Dividend yield | 0.35% |
| Earnings per Share | $45.99 |
| Beta | 0.05 |
| Outstanding Shares | 122,812,110 |
Return
| Return on Equity | 20.10% |
|---|---|
| Return on Assets | 16.82% |
| Return on Invested Capital | 25.41% |
Valuation & Multiples
| P/E Ratio | 25.95 |
|---|---|
| PEG | 50.57 |
| Price to Sales | 6.87 |
| Price to Book Ratio | 5.52 |
| Enterprise Value to Revenue | 6.49 |
| Enterprise Value to EBIT | 19.74 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$12.50
Consensus analyst estimateRevenue Estimate
$6.42 B
Consensus analyst estimateNext Earnings Call
Expected Date
January 28, 2027
EPS Estimate
$11.60
Consensus analyst estimateRevenue Estimate
$6.65 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Alivus Life Sciences Limited
2,272 employees
CEO: Yasir Yusufali Rawjee
Alivus Life Sciences Limited, established in Mumbai, India, in 2001, is a pharmaceutical company that handles the full spectrum of active pharmaceutical ingredient (API) operations, from initial development and meticulous production to w...